Suppr超能文献

熊去氧胆酸治疗胆囊疾病,一个尚未完成的故事。

Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

出版信息

World J Gastroenterol. 2013 Aug 21;19(31):5029-34. doi: 10.3748/wjg.v19.i31.5029.

Abstract

Gallstone disease represents an important issue in the healthcare system. The principal non-invasive non-surgical medical treatment for cholesterol gallstones is still represented by oral litholysis with bile acids. The first successful and documented dissolution of cholesterol gallstones was achieved in 1972. Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic acid (UDCA), demonstrating its extreme versatility. This editorial is aimed to provide a brief review of recent developments in UDCA use, current indications for its use and, the more recent advances in understanding its effects in terms of an anti-inflammatory drug.

摘要

胆石病是医疗体系中的一个重要问题。胆固醇性胆石症的主要非侵入性非手术治疗方法仍然是口服胆酸溶石治疗。1972 年首次成功并记录了胆固醇胆石的溶解。从那时起,全世界的大量研究人员致力于研究熊去氧胆酸(UDCA)的生化和临床研究,证明其具有极高的多功能性。这篇社论旨在简要回顾 UDCA 使用的最新进展、目前的使用适应症,以及最近在理解其作为抗炎药物的作用方面的进展。

相似文献

引用本文的文献

2
Gallstones after bariatric surgery: mechanisms and prophylaxis.减重手术后的胆结石:机制与预防
Front Surg. 2025 Mar 13;12:1506780. doi: 10.3389/fsurg.2025.1506780. eCollection 2025.

本文引用的文献

8
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.依折麦布对胆固醇性胆结石预防及溶解的作用
Gastroenterology. 2008 Jun;134(7):2101-10. doi: 10.1053/j.gastro.2008.03.011. Epub 2008 Mar 10.
9
Gallstone disease: from genes to evidence-based therapy.胆结石疾病:从基因到循证治疗
J Hepatol. 2008;48 Suppl 1:S124-35. doi: 10.1016/j.jhep.2008.01.012. Epub 2008 Feb 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验